Literature DB >> 30714503

Endovascular treatment of dural arteriovenous fistulas with sinus drainage: Do we really need to protect the sinus?

Hans Kortman1, Issam Boukrab1, Menno Sluzewski1, Willem Jan van Rooij1, Jo Pp Peluso2, Charles Majoie3.   

Abstract

BACKGROUND AND
PURPOSE: Dural arteriovenous fistulas (DAVFs) with direct antegrade sinus drainage have a benign natural history but bruit can be disabling. Disconnection of the draining sinus is considered curative. We present the treatment results of 14 patients with a dural arteriovenous fistula with antegrade sinus return with emphasis on functionality of the involved sinus and the need for sinus patency.
MATERIALS AND METHODS: Between January 2009 and January 2018, 14 patients with a DAVF with direct antegrade sinus drainage were treated in our institution. There were two men and 12 women (1: 6) with a mean age of 61 years (median 61, range 43-78). Clinical presentation was unbearable pulsatile bruit in all cases. Thirteen were draining in the sigmoid or transverse sinus and one drained into the inferior petrosal sinus.
RESULTS: Twelve of 14 (86%) patients had a draining sinus non-functional for the brain. In ten of these 12 patients the sinus was occluded with liquid embolic or coils. In the two patients with a functional sinus, the fistula was successfully occluded without occluding the sinus. One patient with inferior petrosal sinus drainage required transvenous embolization. There were no permanent adverse events of treatment.
CONCLUSIONS: Patients with DAVFs with direct antegrade sinus drainage were cured using a strategy of endovascular transarterial and transvenous embolization. Most patients had a non-functional sinus that could be occluded for cure.

Entities:  

Keywords:  Dural arteriovenous fistulas; intracranial; neurovascular

Mesh:

Year:  2019        PMID: 30714503      PMCID: PMC6547210          DOI: 10.1177/1591019918819187

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  7 in total

Review 1.  Dangerous extracranial-intracranial anastomoses and supply to the cranial nerves: vessels the neurointerventionalist needs to know.

Authors:  S Geibprasert; S Pongpech; D Armstrong; T Krings
Journal:  AJNR Am J Neuroradiol       Date:  2009-03-11       Impact factor: 3.825

2.  Endovascular Treatment of Dural Arteriovenous Fistulas of the Transverse and Sigmoid Sinuses Using Transarterial Balloon-Assisted Embolization Combined with Transvenous Balloon Protection of the Venous Sinus.

Authors:  E Piechowiak; F Zibold; T Dobrocky; P J Mosimann; D Bervini; A Raabe; J Gralla; P Mordasini
Journal:  AJNR Am J Neuroradiol       Date:  2017-08-17       Impact factor: 3.825

3.  Natural history of dural arteriovenous shunts.

Authors:  Michael Söderman; Ladislav Pavic; Göran Edner; Staffan Holmin; Tommy Andersson
Journal:  Stroke       Date:  2008-04-03       Impact factor: 7.914

4.  Transvenous balloon-assisted transarterial Onyx embolization of transverse-sigmoid dural arteriovenous malformation.

Authors:  Pakrit Jittapiromsak; Léon Ikka; Nidhal Benachour; Laurent Spelle; Jacques Moret
Journal:  Neuroradiology       Date:  2012-11-21       Impact factor: 2.804

5.  Treatment of cranial dural arteriovenous fistulas with exclusive cortical venous drainage: A single-center cohort of 35 patients.

Authors:  H G Kortman; G Bloemsma; I Boukrab; J P Peluso; M Sluzewski; B van der Pol; G N Beute; C B Majoie; W J van Rooij
Journal:  Interv Neuroradiol       Date:  2017-10-04       Impact factor: 1.610

6.  Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage.

Authors:  C Cognard; Y P Gobin; L Pierot; A L Bailly; E Houdart; A Casasco; J Chiras; J J Merland
Journal:  Radiology       Date:  1995-03       Impact factor: 11.105

7.  Epidemiology of dural arteriovenous fistula in Japan: Analysis of Japanese Registry of Neuroendovascular Therapy (JR-NET2).

Authors:  Masafumi Hiramatsu; Kenji Sugiu; Tomohito Hishikawa; Jun Haruma; Koji Tokunaga; Isao Date; Naoya Kuwayama; Nobuyuki Sakai
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-27       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.